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ABSTRACT 
International Journal of Exercise Science 13(3): 1108-1119, 2020. Breast cancer survivors (BCS) 
experience treatment induced alterations in body composition including the loss of bone mineral density (BMD) 
and lean soft tissue (LST). These changes can affect the metabolism and the systemic inflammatory environment of 
BCS. Objective: To evaluate the differences in body composition, resting energy expenditure (REE), and 
inflammation in BCS and age-matched women without a prior cancer diagnosis (control). Methods: Seventeen post-
menopausal BCS (stages 0-III; age: 59 ± 9 years) and 18 (59 ± 6 years) controls had their total body and regional 
(lumbar spine, femur, and forearm) BMD, LST and fat mass measured via DXA. REE was assessed via 35 minutes 
of indirect calorimetry. Serum concentrations of human C-reactive protein (CRP) were measured via ELISA to 
assess inflammation. Data were analyzed via ANOVAs. Results: There were no significant differences between BCS 
and controls in body composition, metabolic measures and CRP. However, when REE was adjusted for LST, the 
BCS had a significantly greater REE when compared to the controls (p = 0.015). Discussion: Our findings suggest 
that BCS that were on average five years into survivorship appear to have similar body composition, and CRP as 
age-matched women without a prior cancer diagnosis, but significantly different relative REE. 
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Breast cancer is the most prevalent cancer in American women, with an estimated 268,600 new 
cases and 41,760 deaths projected in 2019 (42). Although mortality rates have been declining 
over the decades (42) as a result of increased early detection and improvements in treatment, 
breast cancer survivors (BCS) are often left to live with treatment related side effects (18,37,41). 
Among these side effects, include the acceleration of the negative age-related changes in body 
composition, specifically the loss of both bone mineral density (BMD) and lean soft tissue (LST) 
with the concurrent increase in fat mass (41).  
 
Cancer treatments directly and indirectly increase bone loss and thus the progression to 
osteopenia and/or osteoporosis through various physiologic mechanisms (31). Bone turnover 
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increases in favor of bone resorption as adjuvant chemotherapy agents directly interrupt the 
normal bone remodeling process (19,31). Cancer therapies also affect bone through the reduction 
in circulating estrogen, the hormone that plays a role in increasing bone formation through 
increasing osteoblast activity (31). Chemotherapy indirectly reduces estrogen levels by inducing 
permanent ovarian failure in 50-85% of breast cancer patients (6,20). Whereas, adjuvant 
hormone suppression therapy inhibits estrogen production in adipose tissue through aromatase 
inhibitors (34,36). This creates an imbalance between osteoblastic and osteoclastic activity that 
results in an overall increase in the rate of bone turnover (35).  
 
Decrements in LST during breast cancer, occurs as a result of the catabolic nature of the cancer 
itself, as well as a result of the therapy (18,37,41). Several treatment modalities can influence 
muscle protein synthesis and ultimately muscle mass, leading to losses of the LST compartment 
(mainly composed of muscle mass) (37). Accelerated body composition changes also occur due 
to metabolic alterations (reduced appetite, anorexia, hypercatabolism) induced during tumor-
bearing period (33). Additionally, in cancer patients tumor induced increases in systemic 
inflammation can inhibit the pathways for muscle protein synthesis and promote muscle protein 
breakdown (15). Further, fatigue as a side effect of chemotherapy decreases physical activity 
levels in women undergoing treatment (13), thereby decreasing the mechanical stimuli that is 
needed to maintain skeletal muscle mass. The reduced physical activity levels also promotes the 
accretion of fat mass in women diagnosed with breast cancer due to a reduction in physical 
activity and energy expenditure, thus creating an imbalance between energy intake and 
expenditure (18,41). Elevated levels of body fat increase the levels of circulating inflammatory 
markers, further exacerbating the loss of LST (7). All these factors ultimately create a vicious 
cycle of alterations in all three body composition compartments. 
 
The cancer and/or treatment-related alterations in body composition may lead to phenotypes 
known as sarcopenia (low muscle/lean soft tissue) and sarcopenic obesity (combined sarcopenia 
with excess body weight). Sarcopenia and sarcopenic obesity are prevalent and are predictors 
of poorer prognosis in breast cancer patients (38,39). Among 471 women with stages I-III breast 
cancer, sarcopenia was evident in 16% of the women, and was an independent predictor of 
shorter survival (48). The combined alterations in body composition has been more recently 
characterized as the multifactorial phenotype termed osteosarcopenic obesity (28).  
 
Abnormal body composition may have an impact beyond cancer disease trajectory affecting 
survivorship. Consequences of decrements in LST include reductions in muscular strength 
(1,43) and alterations in metabolism (24) in BCS to a greater extent than that observed with 
normal aging. Changes in body composition and inflammation are also likely to affect resting 
energy expenditure (REE) as a 3% decline in REE was reported in patients receiving adjuvant 
chemotherapy, which remained reduced 3 months after completion of treatment (24). Sustained 
decrements in REE creates an imbalance between energy intake and expenditure that can further 
persist long-term weight gain in BCS (24).  
 
Despite an understanding of the mechanisms contributing to the accelerated age-related 
changes in body composition in early BCS it is unclear whether these differences persist several 
years into survival. Similarly, it is yet to be determined whether associated factors such as 
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increased inflammation and depressed REE exist in BCS several years posttreatment. A 
reasonable follow-up question from the research conducted, is whether the changes in body 
composition, inflammation, and metabolism in BCS that are several years posttreatment is 
attenuated and resembles that of normal aging. Therefore, the aim of this cross-sectional study 
was to compare the differences in body composition and the prevalence of osteosarcopenic 
obesity between BCS and age-matched women without a prior cancer diagnosis (control). A 
secondary aim of the study was to evaluate the differences in the metabolic and inflammatory 





Seventeen post-menopausal female BCS (age: 59 ± 9 years; treated for stages 0-III) and 18 age-
matched women (age: 59 ± 6 years) without a prior cancer diagnosis (control) were recruited via 
flyers posted in the community and recruit through local breast cancer support groups, local 
churches, groups on campus, and community groups. The BCS were at least three months post 
primary (surgery) and adjuvant treatment (chemotherapy and/or radiation). Women currently 
on hormone suppressant therapy were included as these therapies are often prescribed for 10 
years post diagnosis. Women diagnosed with stage IV breast cancer or who had active cancer 
were excluded. The rationale for excluding women with stage IV breast cancer was that these 
women would likely to have the cancer metastasized to the bone and our study aimed to 
compare BCS without metastasized cancer to controls. Participants were excluded if they had 
any physical limitations that would prevent participation in exercise testing, as well as if they 
had hypo or hyperthyroidism, uncontrolled hypertension, uncontrolled diabetes, heart disease, 
kidney disease, or were taking medications known to influence metabolism. This research was 
carried out fully in accordance to the ethical standards of the International Journal of Exercise 
Science (32). The present study was conducted according to the guidelines laid down in the 
Declaration of Helsinki, and all procedures involving human participants were approved by the 
University Institutional Review Board. Written participant informed consent and physician 
consent were obtained before participation in the study. 
 
Protocol 
Eligible participants were scheduled for two testing visits, each separated by one week. During 
the first visit, participants completed a demographics and medical history questionnaire. 
Participants returned to the laboratory after an 8 hour fast between 6:00 AM and 9:00 AM for 
their second testing visit, which included blood collection and assessments of resting energy 
expenditure and body composition. The laboratory testing visits were separated by at least 
seven days.   
 
Prior to testing, participants were asked to refrain from exercise, caffeine, and alcohol for 24 
hours and reported to the laboratory between 0600 and 0900 hours. Fasting (>8 hours) venous 
blood samples in the amount of 20 milliliters were collected from the antecubital space to 
measure serum levels of human C-reactive protein (CRP) as measures of systemic inflammation. 
Due to the scope of this study, this biomarker was chosen in order to understand the possible 
relationships between diet, body composition and inflammation in breast cancer survivors as 
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well as compare these variables to healthy age-matched women. Serum CRP levels greater than 
3.0 mg/L was used to determine the presence of low grade chronic inflammation in the present 
study (21). Analysis of serum CRP was conducted at the conclusion of the study via one enzyme-
linked immunosorbent assay (R&D Systems®). The serum samples were run in duplicate and 
the intra-assay coefficient of variation (CV) was 19.4%. Samples with a CV >20% were excluded 
from analysis.  
 
Following the blood draw, the participants had their REE, and non-protein respiratory quotient 
(RQ) measured via indirect calorimetry using the ventilated hood technique (ParvoMedics 
TrueOne 2400, Sandy, Utah). The participants were asked to lay supine on a padded table in a 
dark, quiet and climate-controlled room for a total of 1 hour and 5 minutes, which comprised of 
30 minutes at rest, then 35 minutes of continuous gas exchange measurements with the 
ventilated hood covering the head and torso. The final 30 minutes of gas exchange 
measurements were used to determine oxygen consumption (VO2; ml/kg/min), predicted 24 
hour REE (kcal/day) and REE adjusted for LST (kcal/day/kg) to use for analysis.   
 
Upon completion of the REE assessment, height and weight were measured using stadiometer 
and scale, respectively (Seca Corporation; Hanover, MD) to calculate the body mass index (BMI; 
kg/m²). Body composition was measured via dual energy X-ray absorptiometry (DXA; Prodigy 
Advance, GE Medical Systems; Madison, WI). The BMD of the lumbar spine (L1-L4), right and 
left femoral neck, and right and left forearm were measured and analyzed by the same licensed 
technician according to manufacturer’s guidelines and specifications. In addition, total body and 
regional LST, fat mass, and percent body fat were measured via DXA. The appendicular skeletal 
muscle mass index (arm + leg LST) adjusted by height (ASMI; kg/m²) was calculated to 
determine the presence of sarcopenia. In the present study, the presence of osteosarcopenic 
obesity was determined according the criteria defined by Ilich et al. (28) as having a T-score < -
1.0 standard deviations below the mean of young adult reference values at the lumbar, or 
femoral neck. Sarcopenia was defined as having an ASMI of <5.45 kg/m² (5). Obesity was 
defined as having a DXA derived fat mass >32%. 
 
Statistical Analysis 
Descriptive statistics including mean and standard deviation were determined for all variables. 
Dependent variables were analyzed via a one-way analysis of variance (ANOVA). When 
Levene's test for equality of variances was violated, the Welch ANOVA was used to compare 
group differences. All significance was accepted at p < 0.05. Statistical Analysis was done using 




A comparison of participant descriptive data between BCS and controls as well as the cancer 
history of BCS are displayed in Table 1. There were no significant differences between BCS and 
controls in all variables except for menopausal age. The BCS entered menopause at a 
significantly younger age than the controls (p = 0.042). Thirty-three of the participants were 
Caucasian and two were Asian. 
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Table 1. Descriptive characteristics of participants.  
 BCS (n = 17) Controls (n = 18) 
Age (years) 59±9 59±6 
Menopause age (years)* 47±4 50±4 
BMI (kg/m2) 26.4±5.1 25.3±3.8 
Time since diagnosis (months)  76.4±17.8 . 
Time since primary treatment completed (months) 75.7±17.8 . 
Time since completion of hormone therapy 
(months)  37.8±22.9 . 
Stage 0 (%) 6.3% . 
Stage I (%) 62.5% . 
Stage II (%) 12.5% . 
Stage III (%) 18.8% . 
Values are mean ± SD; BCS = breast cancer survivors; BMI= body mass index; * p < 0.05 indicates statistically 
significant difference between BCS and controls. 
 
Table 2 presents the measures of body composition. Lean soft tissue, fat mass, ASMI and total 
body fat did not differ between the groups. Similarly, there were no significant differences in 
any BMD measures. Table 3 presents a comparison of the criteria for osteosarcopenic obesity. 
Based on these criteria, only one participant, a BCS was classified as having osteosarcopenic 
obesity. 
 
Table 2. Comparison of body composition measures between BCS and controls. 
 BCS (n = 17) Controls (n = 18) P-value 
LST (kg) 38.1±4.5 38.4±3.9 0.817 
Fat Mass (kg) 28.3±9.4 26.6±7.6 0.568 
ASMI (kg/m2) 6.22±0.9 6.04±0.9 0.479 
Total Body Fat (%) 41.6±7.1 39.8±6.2 0.442 
Lumbar BMD (g/m2) 1.097±.0186 1.064±0.185 0.607 
Left Femoral Neck (g/m2)‡ 0.851±0.080 0.878±0.091 0.367 
Right Femoral Neck (g/m2) ‡ 0.807±0.211 0.859±0.083 0.340 
Left Femur (g/m2) ‡ 0.924±0.091 0.916±0.093 0.815 
Right Femur (g/m2) ‡ 0.928±0.099 0.906±0.097 0.507 
Left Radius Total (g/m2) 0.592±0.087 0.607±0.043 0.538 
Right Radius Total (g/m2) 0.606±0.089 0.603±0.055 0.882 
Values are mean ± SD; BCS = breast cancer survivors; LST = lean soft tissue, ASMI = appendicular skeletal 
mass index; BMD = bone mineral density; ‡ n = 16 for BCS group because one participant had dual hip 
replacement. 
 
Table 3. Prevalence of osteosarcopenic obesity criteria between BCS and controls. 
 BCS (n = 17) Controls (n = 18) 
Low BMD Lumbar Spine (L1-L4) ‡ 7 (41.2) 3 (16.7) 
Low BMD Left Femoral Neck‡ 12 (70.6) 9 (50.0) 
Low BMD Right Femoral Neck‡  13 (76.5) 12 (66.7) 
Sarcopenia 2 (11.8) 1 (5.6) 
Obesity 16 (94.1) 17 (94.4) 
Sarcopenic Obesity  1 (5.9) 0 (0.0) 
Osteosarcopenic Obesity 1 (5.9) 0 (0.0) 
Values are n (% of sample); BCS = breast cancer survivors; ‡ Low BMD classified as T-score < -1 SD 
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A comparison of the metabolic measures between BCS and controls are presented in table 4. One 
participant from each group did not complete the metabolic assessments due to feelings of 
claustrophobia when laying under the ventilated hood. There were no significant differences 
between BCS and controls for resting VO2, predicted REE, and respiratory quotient. However, 
when REE was adjusted for LST, the BCS had a significantly greater REE when compared to the 
controls (p = 0.015).  
 
Table 4. Comparison of metabolic and inflammatory measures between BCS and controls.  
 BCS (n = 17) Controls (n = 18) P-value 
Metabolism    
VO2 (ml/kg/min) 2.94 ± 0.39 2.87 ± 0.77 0.758 
REE (kcal/day) 1381 ± 191 1270 ± 184 0.099 
REE adjusted for LST (kcal/day/kg) 36.1 ± 2.22 33.0 ± 4.3 0.015 
Respiratory Quotient  0.73 ± 0.04 0.75 ± 0.05 0.116 
Inflammation    
CRP (mg/L) ‡ 3.74 ± 1.45 3.34 ± 1.64 0.263 
Values are mean ± SD; BCS = breast cancer survivors; VO2 = oxygen consumption; REE = resting energy 
expenditure; LST = lean soft tissue; CRP = C-reactive protein; ‡ n = 13 for BCS and n = 9 for controls. *p < 0.05, 
significant difference between BCS and controls. 
 
Table 4 also presents the serum levels of the inflammatory marker CRP. Three participants from 
each group had unsuccessful blood draws and thus were not able to have CRP measured. In 
addition, one BCS and four controls had CVs greater than 20% and were thus excluded from 
analysis. Therefore, thirteen BCS and nine controls had CRP levels analyzed. There were no 
significant differences in CRP levels between BCS and controls. However, more BCS (n = 9) did 




The main findings of our present study are that BCS that are 75.7 ± 17.8 months (6.31 ± 1.5years) 
after completion of primary treatment have greater relative REE compared to controls. 
However, the BCS in our study had similar body composition, absolute REE, RQ, and circulating 
CRP levels. Despite BCS having menopause at a significantly younger age, the BMD at several 
skeletal sites and the prevalence of osteoporosis, sarcopenia, and osteosarcopenic obesity also 
did not differ from controls. 
 
Our findings of similar body composition measures (LST, fat mass, ASMI, total body fat and 
BMD) between BCS and controls is in agreement to previous studies investigating BCS that are 
on average more than 5 years posttreatment (3,43). In contrast to our findings, Twiss et al. (46) 
observed that more BCS had low BMD in the lumbar spine when compared to the femur. In 
addition, the work from Simonavice et al. (43) found that total forearm BMD was 11% lower in 
BCS when compared to controls, and the difference in forearm BMD was confirmed by a more 
recent study by Artese et al. (3). However, our findings of no differences in lumbar spine and 
femur BMD are consistent with previous findings (3,12,43). Whereas, Ferreira Poloni et al. (17) 
observed that osteopenia and osteoporosis in the femoral neck was more prevalent in BCS (14.5 
± 8.5 years post-menopause) when compared to controls with a similar time since menopause. 
Further, across all skeletal sites, low bone mass (osteopenia or osteoporosis) was present in 77% 
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of BCS compared to 74.5% in controls (17). Despite the lack of significant differences in BMD 
between BCS and controls in the present study, more BCS had low BMD (T-score <-1.0) at the 
lumbar (41.2 vs. 16.7%) and left femoral neck (70.6 vs. 50.0%). Although our sample is small, the 
prevalence of low BMD in our study at the lumbar spine (41.2 vs. 45.7%) is similar that observed 
in 70 BCS (53.2 ± 5.9 years) that were also ~5 years post-diagnosis (11). However when 
comparing BMD at the femoral neck, our BCS had a greater prevalence of low BMD (76.5 vs. 
28.6%) than the BCS in the study by Conde et al. (11).  
 
These differences between our findings and those of Conde et al. (11) may be due to our BCS 
being slightly older (59 ± 9 vs. 53 ± 6 years), despite more of our BCS being diagnosed at an 
earlier stage (stage 0 or I: 68.8 vs. 28.5%) and having a slightly greater time since diagnosis (76.4 
± 17.8 vs. 65.2 ± 55.1 months). Although it has been reported that age- and hormonal-related 
decrements in BMD cause greater losses of BMD at the lumbar spine than the femur (10,53), not 
all studies agree (47,50). In fact, there are several factors that have been associated with the site-
specific BMD changes including BMI (47,50,52), LST (26), postmenopausal status (29) and a 
longer time since diagnosis (11,53). Despite the lack of group differences, our findings highlight 
the prevalence of low BMD in postmenopausal women regardless of cancer diagnosis that is 
consistent with existing literature. Although several exercise and/or nutritional interventions 
have been conducted to address low BMD in BCS (45,52) and cancer-free postmenopausal 
women (2,27,49), more work is needed in this area. Particularly since low BMD is associated 
with up to a 4.0 fold increase in the rate of fractures in postmenopausal women (45). 
Interestingly, only one BCS had sarcopenic obesity in our study. This low prevalence, although 
positive, may be due to our small sample size, with the majority of our BCS being greater than 
5 years post treatment and being primarily diagnosed with stage I (62%). Thus, they may not 
experience the decrements that recent survivors and more advanced stage BCS may experience.   
 
Although not all BCS are overweight and obese, it is has been consistently reported that BCS 
experience significant weight gain (14,18). This may lead to some metabolic disturbances related 
to increased adiposity including insulin resistance, dyslipidemia, and chronic inflammation 
(16,31). The present study sought to determine whether BCS several years after diagnosis had 
greater metabolic disturbances as determined by absolute and relative REE as well as CRP to 
measure inflammatory status. Absolute REE and inflammation were similar between BCS and 
controls. However, when REE was adjusted for LST, the BCS had a significantly greater REE 
than the controls. The majority of BCS (94.1%) and controls (94.4%) in the present study were 
classified as obese based on body composition (body fat > 32%), despite mean BMI values that 
only classified both the BCS and controls as overweight (26.4 ± 5.1 and 25.3 ± 3.8 kg/m²). Data 
surrounding changes in REE within the cancer population are conflicting (23,24,26). Campbell 
et al. (8) did not observe a change in REE in 10 breast cancer patients undergoing adjuvant 
chemotherapy, despite an increase in fat mass. Other studies (9,24,25) have observed increases 
in REE in cancer populations primarily during the tumor-bearing period. These observed 
increases in REE have led to up to 73% of cancer patients being reported to experience some 
degree of accelerated body composition changes such as weight loss (muscle and fat) during 
their disease course (33,40).  
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Further, these changes in REE occur primarily in cancers of metabolically active organs (e.g. 
liver, pancreatic) (33). However, during and after treatment REE may decrease and remain 
depressed in the months following completion of primary treatment (24). A study by Guinan et 
al. (22) stratified 69 BCS (age: 53.4 ± 9.39 years) that were 3.1 ± 1.0 years post diagnosis into four 
groups based on abdominal obesity (waist circumference) and insulin resistance and compared 
both the absolute REE and REE adjusted by fat-free mass among the BCS. The BCS with the 
worst metabolic profile (waist > 88cm and insulin resistant) had significantly greater REE and 
CRP than the BCS with healthier metabolic profiles (normal waist circumference and/or absence 
of insulin resistance). Interestingly, objectively measured habitual physical activity levels were 
not associated with REE in the cohort of BCS investigated by Guinan et al. (22). The average 
absolute REE of the group with the worst metabolic health (waist > 88cm and insulin resistant) 
was greater than our BCS (6191 ± 959 vs. 5776 ± 798 kJ/day), whereas the LST adjusted REE was 
lower compared to the BCS in the present study (122 ± 10.7 vs. 151 ± 9.31 kJ/day/kg). Similarly 
in a large study by Cao et al. (9), REE was not different between newly diagnosed cancer patients 
from various cancer types and healthy controls. However, when REE was adjusted to fat-free 
mass, the cancer patients had significantly higher REE regardless of age and gender (9). Thus, 
the findings of our small pilot study suggest that BCS > 5 years posttreatment may have unclear 
or similar metabolic function as age-matched women without a prior cancer diagnosis. It is 
possible that a tumor developed in breast tissue may not result in a significant metabolic burden 
as compared to tumors in more metabolically active organs (e.g. liver, pancreas) (9).  
 
The present study also measured the acute-phase reactant CRP to determine the inflammatory 
status of our participants. Similarities in the body composition of our participants may explain 
the lack of differences in serum CRP between the BCS and controls. Despite the lack of group 
differences, more BCS (53%) had chronic low-grade inflammation (CRP > 3.0 mg/L) compared 
to controls (16%). The average CRP values of the BCS (3.74 ± 1.45 mg/L) and controls (3.34 ± 
1.64 mg/L) in the present study were greater than the BCS in the normal to moderate weight, 
non-insulin resistant groups (1.53-2.09 mg/L) but less than the obese, insulin resistant BCS (4.98 
± 3.46 mg/L) in the study by Guinan et al. (22). Therefore, it is unclear if the interaction between 
body composition and metabolic profiles differs in BCS several years posttreatment with that of 
age-matched women without a prior cancer diagnosis. Nevertheless, evidence suggests a 
significant association between elevated CRP with increased risk of and reduced survival from 
breast cancer (4). Further, survivors in a chronic state of inflammation have a higher chance of 
cancer recurrence and metabolic disturbances (4). Thus, regardless of cancer diagnosis, 
interventions to reduce chronic inflammation are necessary for postmenopausal women.  
 
It is important to note that the BCS in the present study were primarily diagnosed with stage I 
breast cancer (62%) and 59% of our BCS were treated with chemotherapy. In addition, we 
determined that only 2 BCS in our sample had low muscle mass (sarcopenia). Therefore our 
findings suggest that the amount of LST plays a role in the comparable metabolism between the 
BCS and postmenopausal women in our study. This highlights the importance of maintaining 
and/or regaining LST in BCS. Whether metabolism differs in BCS that had a more advanced 
stage diagnosis still needs to be determined.  
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The present study did have some limitations. First, this cross-sectional study had a relatively 
small sample size of BCS and controls, therefore future studies including larger sample sizes are 
needed to confirm our findings. Secondly, we did not collect physical activity and dietary data 
that may explain the similarities between BCS and controls. Lastly, our study contained a 
heterogeneous sample of BCS that differed in their diagnosis, time since diagnosis, and type of 
treatment which may have affected the extent of side effects experienced. Therefore, differences 
between BCS and controls in our main outcome measures may have been attenuated. 
 
In conclusion, our small study shows BCS that are on average several years post-completion of 
primary treatment have similar body composition, absolute REE, RQ, and circulating CRP levels 
to age-matched women without a prior cancer diagnosis. However, when REE was adjusted for 
LST, the BCS had greater relative REE compared to controls. More research studies with larger 
sample sizes of BCS are needed to determine if the accelerated treatment related decrements in 
these health outcomes extend far into the survival years. In addition, larger studies may 
determine if the similar health outcomes in BCS are in fact a result of more proactive and health 
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